Loading stock data…
JNJ
$229.85+2.50 (+1.10%)
Market ClosedLast close Apr 30
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $229.85. The stock is currently 9% below its 52-week high of $251.71, remaining 12.4% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why JNJ maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
UNHPFEABBV
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$229.85
Potential Upside
14.9%
Whystock Fair Value$264.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Buy
Mean target$252.42+9.8%
Range$155.00 – $285.00
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$544.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
237.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.79%
Volume
Today's trading volume
8.14M
Recent News
Microsoft says it has over 20M paid Copilot users, and they really are using it
Despite the lingering perception that no one really uses Copilot, Microsoft said on Wednesday that the number of users and engagement is growing.
AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock.
AbbVie stock rose Wednesday after the pharmaceutical company reported better-than-expected quarterly earnings. AbbVie lifted its guidance for adjusted per-share earnings in 2026 to between $14.08 and $14.28, from a previous range of $13.96 to $14.16. Shares of AbbVie rose 3.1% to $203.90 in afternoon trading.
46% of Americans Split Their Investments Into Separate Buckets. Should Your Retirement Strategy Too?
The Charles Schwab Modern Wealth Survey 2025 found that 46% of American investors maintain a main investment portfolio alongside one or more smaller, separate portfolios designated for different financial goals, while 39% still rely on a single portfolio for everything, and 15% run multiple portfolios used roughly equally. Among those running multiple accounts, 54% say ... 46% of Americans Split Their Investments Into Separate Buckets. Should Your Retirement Strategy Too?
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira and Imbruvica declines.
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.